Acta Pharmaceutica Sinica B
|
2026, 16(1): 647-650
• Letters to the editor •
Rifamycin O as a novel CRBN ligand for targeted degradation of IKZF1/3 proteins in hematopoietic malignancies
Full
Liang Liao, Qiang Wang, Zhengyang Gao, Jiayao Liu, Yuxuan Tong, Xin Chen, Jin Zhu, Jian Li, Jinlian Wei
Affiliations
doi: 10.1016/j.apsb.2025.10.033
Outline
CRBN
/
Fluorescence polarization
/
Rifamycin O
/
Novel ligand
/
Hematopoietic malignancies
/
IKZF1/3
/
Molecular glue
/
Proteasomal degradation
Liang Liao, Qiang Wang, Zhengyang Gao, Jiayao Liu, Yuxuan Tong, Xin Chen, Jin Zhu, Jian Li, Jinlian Wei.
Rifamycin O as a novel CRBN ligand for targeted degradation of IKZF1/3 proteins in hematopoietic malignancies[J].
Acta Pharmaceutica Sinica B,
2026
, 16
(1)
: 647
-650
.
DOI: 10.1016/j.apsb.2025.10.033
Year 2026 volume 16 Issue 1
PDF
5
3
Cite this Article
BibTeX
Article Info
doi: 10.1016/j.apsb.2025.10.033
- Receive Date:2025-01-27
- Online Date:2026-09-17